small molecule

ITOVEBI

INAVOLISIB

Loss of exclusivityJune 2038latest FDA-listed patent expiry

CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand name	ITOVEBI
Active ingredient	INAVOLISIB
Strength	3MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	October 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
12410189	June 2038	use U-4024
11028100	April 2038	substance, product
10851091	July 2036	substance, product
9650393	July 2036	substance, product
11760753	July 2036	use U-4024
8343955	September 2030	use U-4024
8242104	September 2030	substance, product

Regulatory exclusivity

Code	Expires
NCE	October 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Genentech